


CORPORATE PRESENTATION

September 2021




The following presentation has been prepared by Genetron Holdings Limited (“Genetron Health” or the “Company”) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document contains certain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1953, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company’s future financial or business performance, strategies or expectations. These statements typically contain words such as “believe,” “may,” “will,” “could,” “expects” and “anticipates” and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement and involves known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. There can be no assurance that the results and events contemplated by the forward looking statements contained herein will in fact occur. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of assumptions, fully stated in the document. The Company also cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time and which may be beyond the Company’s control. The Company assumes no duty to and does not undertake to update any forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting these statements. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission.

This document also contains non-IFRS financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with International Financial Reporting Standards. In addition, the Company’s calculation of these non-IFRS financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. The reconciliation of those measures to the most comparable IFRS measures is contained within this document or available at our website <http://ir.genetronhealth.com>.

This document speaks as of September 10, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

1	Company Overview
2	Market Overview
3	Diagnosis & Monitoring
4	Proprietary Tech Differentiates Our Products
5	Biopharma Services – CDx development
6	Early Screening: R&D, Progress, Strategy and Commercialization
7	MRD New Product Line; Future Strategies and Growth Drivers
8	Financial Overview



Mission

**Transform full-cycle cancer management globally
by driving technological innovation and
accelerating the adoption of precision medicine**


———— GENETRON 泛生子 ————




GENETRON 泛生子

ANSWERS FOR CANCER


Company Overview



China's Leading Precision Oncology Company Targeting US\$50B+ TAMs



Source: 1. Frost & Sullivan - Market potential in China as of 2023; 2. Euromonitor, Globalcan, Company internal estimates.





Sizhen Wang
MBA
CEO and Director



Hai Yan
M.D./Ph.D.
CSO and Director



Yuchen Jiao
M.D./Ph.D.
CTO



Evan Xu
CFO



Yunfu Hu
Ph.D.
CMO







GENETRON 泛生子

ANSWERS FOR CANCER


Market Overview




China has the Largest Number of Cancer Patients Globally



Mostly late stage diagnosis



Cancer molecular profiling penetration rate




Source: Frost & Sullivan

Historical Opportunity of Precision Oncology in China: Supportive Policies

- Precision medicine is listed as a **strategic emerging industry in the 13th Five-Year Plan**
- By 2030, the State will invest more than **RMB60bn** in precision medicine, including **RMB20bn from the central government**¹
- **State Council policy briefing** targeted to focus on liver cancer and lung cancer and **optimize the early screening program**
- After the COVID-19 outbreak in 2020, the State requires hospitals at the county level and above to establish capability for nucleic acid (molecular) testing², which **further expands the market**
- Newly released **Regulations on Supervision and Administration of Medical Devices** provide guidance on disciplined and healthy development of laboratory developed test (LDT)
- Gene methylation testing is included in **Beijing's Class A Medical Insurance and Class A Work Injury Insurance projects**

Healthy China 2030:

Cancer patients 5-year survival rate will increase to 46.6% by 2030



Source: Frost & Sullivan, www.gov.cn

¹ Ministry of Science and Technology (MoST)'s first panel meeting on strategy of precision medicine


² The Notice on Further Work Related to COVID-19 Testing During the Pandemic.



GENETRON 泛生子

ANSWERS FOR CANCER

Diagnosis & Monitoring



LDT + IVD Business Model

Laboratory developed test (LDT)


- Initially hospitals unable to run complex NGS testing in house
- Third party labs provide service to hospitals
- Fast adoption of latest technology



In vitro diagnostics (IVD)

- Generate incremental revenue for hospitals
- Currently the only pathway to public medical insurance
- Lengthy large size clinical trials required by NMPA

We provide LDTs to ~500 top hospitals in China, we are also promoting IVD product in hospital market



Targeting **~1000** Class 3 Grade A hospitals for cancer treatment in China

300+ Internal direct sales and marketing representatives


LDT

500+ hospitals ordered tests from us

IVD

Teamed up with **SIEMENS Healthineers** to advance the use of **Genetron S5 platform and lung cancer 8-gene IVD assay in hospitals**










Number of In-hospital Partners



¹ The number of total in-hospital partners include both sales of LDT services and IVD products.

² By June 30, 2021

- Cover **top 10** prevalent cancers in China
- **Onco PanScan**: one of the largest gene panels
- Include **tissue** and **liquid** biopsy
- Able to detect a broad spectrum of **alterations**


Cancer Types	Diagnosis	Monitoring
 Pan-cancer (Onco PanScan)	● ●	●
 CNS	● ●	●
 Lung	● ●	●
 Gastric	● ●	●
 Colorectal	● ●	●
 Thyroid	●	
 Breast	●	
 Bladder	●	●
 Hematologic	●	●

LDT service menu ● Tissue ● Blood ● Urine ● CSF

Onco PanScan™

- 125 target genes
- 45 chemosensitive sites
- 90 immune-related genes
- Match 250 types of targeted drugs
- TMB, MSI

IVD: Commercial Portfolio and Registration Pipeline



* Including software

Sequencing platforms of different throughput targeting various institutional settings....



...assays covering diagnostics, monitoring and early screening

Prevalent IVD platform in China¹

qPCR

Name	Cancer type	Type	Sample type	Status
IDH	Brain	Diagnosis	Tissue	Approved
TERT	Brain	Diagnosis	Tissue	Approved
Thyroid	Thyroid	Diagnosis	Tissue	Clinical trial

Genetron 3D biochip reading instrument



dPCR

- Low throughput
- Approved in 2017

Name	Cancer type	Type	Sample type	Status
T790M ctDNA	Lung	Diagnosis & Monitoring	Blood	Clinical trial

Genetron S5



NGS

- Medium throughput
- Approved in 2019

Name	Cancer type	Type	Sample type	Status
Lung 8	Lung	Diagnosis	Tissue	Approved
EGFR ctDNA	Lung	Diagnosis & Monitoring	Blood	Clinical trial
Bladder	Bladder	Diagnosis & Monitoring	Urine	Pre-clinical
Glioma 8	Brain	Diagnosis	Tissue	Pre-clinical

Genetron S2000



NGS

- High throughput
- Approved in 2020

Name	Cancer type	Type	Sample type	Status
Onco PanScan ^(TS)	Pan-cancer	Diagnosis	Tissue	Technical Specification & Device Evaluation

¹ Non-Genetron's products




GENETRON 泛生子

ANSWERS FOR CANCER


Proprietary Tech Differentiates Our Products

Proprietary One-Step Seq Method Presents Significant Advantage For Hospitals in China

Genetron One-Step Seq vs Amplicon / Hybridization based methods



OneStep-seq



GENETRON 泛生子

Qubit/ nanodrop sequencing

Multiplex PCR 1h

Reaction: 5-20 min (Green bar)


Purification: 20 min (Blue circle)

With risk of contamination (Red line)

Hands-on steps	Very simple (10 min)
Total time (from DNA to library)	1.5 hours
Contamination risk	Low
Laboratory section requirement	Low

VS

Ampli-seq



Multiplex PCR 2h

Digest primer 1h

ligation 1.5h


qPCR 1.5h

sequencing

With risk of contamination (Red line)

Hands-on steps	Complicated (40 min)
Total time (from DNA to library)	8 hours
Contamination risk	High
Laboratory section requirement	Medium

Hybridization capture



Fragmentation

End Repair /dA 1h

ligation 0.5h

PCR 0.5h

Hybridization: MIX 12h

hybridization

Bead mixed

Wash1

W2 elution


PCR 1h

qPCR 1.5h

sequencing

With risk of contamination (Red line)

Hands-on steps	Very complicated
Total time (from DNA to library)	24 hours
Contamination risk	High
Laboratory section requirement	High



¹ Based on Company's estimate.



Lung Cancer 8-Gene Kit



Genetron S5

Accurate Testing

High sequencing consistency, repetition rate and accuracy

Speedy Process

Two-day turn around time

Small Sample Demand

As little as 20ng of sample DNA

Companion diagnostics becomes indispensable with the development of targeted therapies in NSCLC



Comprehensive 8-Gene Coverage

Gene	Chinese Population Mutation Rate ^[1]
EGFR	50.1%
KRAS	12.3%
BRAF	4.4%
PIK3CA	12%
HER2	6.3%
ALK	7.8%
ROS1	1.3%
MET	3.4%



New Commercialization Opportunity

Received **CE Mark for 8-gene Lung Cancer Assay**, the second regulatory milestone for this assay and a new commercialization opportunity

[1] *Oncologist*. 2019 Nov;24(11):e1070-e1081.




GENETRON 泛生子

ANSWERS FOR CANCER

Biopharma Services – CDx development

FDA approved CDx for NSCLC



Source: FDA

Collaboration with Biopharmas throughout the whole process of new drug discovery
Driving Co-development of therapeutic drugs and companion diagnostics



AstraZeneca

Roche

BAYER

HANSOH PHARMA

FOSUN 复星

正大天晴
CHIATAI TIANQING

康宁杰瑞
ALPHAMAB ONCOLOGY

Innovent
信达生物制药

亚盛医药
Ascentage Pharma

dMed
缔脉

INNOCARE
Science Drives Innovation

基石药业
CSTONE PHARMACEUTICALS

EDIGENE
博雅辑因

合源生物
JUVENTAS

Strategic partnership with ~40 leading global and China biopharmas

Note: As of June 30, 2021



- CLIA (2)
- CAP (2)
- NCCL EQA Certification

Laboratories


Beijing, Shanghai, Wuxi⁽¹⁾, Chongqing, Guangzhou⁽³⁾, Maryland



- GMP for medical devices
- ISO 13485:2016
- ISO 9001 2015
- ISO:15189:2012²

Manufacturing facilities

Beijing, Chongqing
Designed annual capacity of **100,000 assays** and **500 sequencing platforms**



Headquarters

Manufacturing facility

Testing facility

R&D center



Onco PanScan **large-panel** LDT recommended for **pilot run** by Guangzhou government

Working with regulators to formulate industry standards

¹ Wuxi facility is under construction

² Beijing laboratory facility is both CLIA and CAP certified, and obtained various ISO certifications; Maryland lab in the US is CLIA certified


³ Guangzhou Lab is newly established and currently pending certifications



GENETRON 泛生子

ANSWERS FOR CANCER

Early Screening: R&D, Progress, Strategy and Commercialization



- ### Features & Advantages
- In parallel profiling of mutation and methylation markers
 - De novo* discovery of methylation sites
 - Support **multiple tests** from a single ctDNA sample
 - Strong performance** with significant time and cost savings


Source: Pantel et al., Nat Rev Clin Oncol, 2019

Genetron's groundbreaking study published in Mar 2019

✓ Study based on collaboration with **National Cancer Center of China**: government funded semi-annual follow-up and blood sample collection




✓ China's **only prospective and peer-reviewed study** published on liver cancer early screening




¹ Training cohort on patients who had liver nodules and/or elevated serum AFP levels.

HCCscreen™ Investigational Study (the “HIT” study)


- ✓ Collaboration study started in 2019 with the National Cancer Center
- ✓ Multi-center study
- ✓ 2,000 HBsAg+ patients were tested by HCCScreen™ and Ultrasound + AFP
- ✓ Completed follow-up work for 1,615 cases




Sensitivity
(76/86)
95%CI
(80%, 94%)



Specificity
(1,419/1,529)
95%CI
(91%,94%)



Positive Predictive Value (PPV)
(76/186)



Negative Predictive Value (NPV)
(1,419/1,429)

HCCscreen™ demonstrated superior sensitivity and comparable specificity versus SOC (Ultrasound+AFP)


Sensitivity

95% CI,
80%-94%



■ HCCScreen (n=1615)


95% CI,
60%-80%



■ Ultrasound+AFP


Specificity

95% CI,
91%-94%



■ HCCScreen (n=1615)

95% CI,
93%-96%



■ Ultrasound+AFP

Clinical Diagnosis

HCCscreen™ Test	HCC	Non-HCC	Total
Test - Positive	76	110	186
Test - Negative	10	1,419	1,429
Total	86	1,529	1,615

- HCCscreen™ demonstrated **excellent sensitivity in detecting early-stage HCC**
- These patients are expected to have much better prognosis than advanced-stage

Detection Range of HCCscreen™

Golden Treatment Period

Detection Range with Traditional Method

Very Early Stage

Early Stage

Mid Stage

Late Stage




Tumor size <3cm

Distant metastasis

5-year survival rate **80%-90%**


High Mortality Rate


Sensitivity



HCCscreen™ Test	Tumour Size	<3cm	3-5cm	>5cm	Total
	Test Positive	28	22	7	57
Test Negative	5	1	1	7	
Total	33	23	8	64	

First Mover Advantage in Early Screening Commercialization




- Powered by Genetron's innovative and proprietary **Mutation Capsule** Technology
- Received **U.S. FDA** breakthrough designation – expands geographical reach 

iKang 爱康

Service available at 100+ iKang medical exam centers nationwide

JDH 京东健康

Aim to jointly create an internet innovation model for full-cycle cancer solutions



NCC
NATIONAL CANCER CENTER
国家癌症中心

Collaborated with local governments for public health initiatives
Wuxi Huishan in Jiangsu (江苏省无锡市惠山区)
Bijie Dafang in Guizhou (贵州省毕节市大方县)

正大天晴药业集团
CHIA TAI TIANQING PHARMACEUTICAL GROUP

Partnership with CTTQ, a subsidiary of SBP (1177.HK), which has great access to China's hepatitis hospital market

US\$7.2bn

Liver Cancer Early Screening Market Size



- 150,000 HCCscreen™ tests large-scale adoption + LDT launch
- Prospective cohort of 1,615 patients reported encouraging data
- NMPA registration: trial initiation in 2021
- NMPA approval projected in 2023

US\$5.8bn


Lung Cancer Early Screening Market Size



- Leveraging Mutation Capsule™ technology to establish early screening models for lung and digestive system cancers
- Aug 2020: Joined **China National Key R&D Project** led by MOST, launched over **100,000 patient cohort** each for lung and digestive system cancers
- Case-control **CRC** study preliminary data in 2021

US\$23.0bn

CRC Early Screening Market Size



- Mutation Capsule™ allows cross-validation of studies for each individual cancer types
- Develop **multi-cancer early screening** model covering several major cancer types with good performance



MRD New Product Line; Future Strategies and Growth Drivers


GENETRON 泛生子

ANSWERS FOR CANCER



Seq-MRD[®] for Blood Cancer with "One-Step Seq" Method


Seq-MRD[®] Workflow



Features and Advantages

- High sensitivity and stability
- Simple operation, low risk of contamination
- Wide clonotype coverage

- Leveraging our **One-Step Seq** technology, Seq-MRD[®] can be used to **detect and monitor MRD in patients with hematological tumor**
- Seq-MRD[®] provides more accurate evidence for **early treatment response and recurrence prediction**
- Inked a partnership with a **leading MNC** and expect to be launched in clinical settings soon




Source:
Short, NJ, Jabbour, E, Albitar, M, et al.
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. *Am J Hematol.* 2019; 94: 257- 265.
<https://doi.org/10.1002/ajh.25338>

MRD: Minimal residual disease.

Solid Tumor MRD development

MRD (Minimal Residual Disease) as an important indicator for prognosis, drug resistance and recurrence



Most accurate; But higher cost, longer process,
and tissue sample required

Multi-biomarker panel, no tissue sample required
Allows broader adoption

Focused on Transforming the Lifecycle Management of Cancer over the Next Three Years

Early Screening

2021:

- ✓ Data readout for large-scale prospective liver cancer screening trial
- HCCscreen registrational trial initiation
- Data readout for colorectal cancer early screening

2023:

- HCCscreen approval

MRD¹ Detection

2021:

- Product launch for hematological tumor MRD¹

2021-22:

- Data readout for solid tumor MRD


Medication Guidance

2021:


- OncoPan Scan large-panel registrational trial initiation
- Avapritinib companion diagnostic kit approval

2022:



- Blood-based small panel for lung cancer
- Tissue-based small panel for thyroid cancer



¹ Minimal residual disease.



- Develop liquid biopsy-based solutions across the full-cycle cancer management
- Continue to ramp up our commercialization efforts





GENETRON 泛生子

ANSWERS FOR CANCER




Financial Overview


2Q2021 revenue growth drivers:

- Sales of LDT services included sales of our early screening test, HCCscreen
- Increased IVD revenue was driven by increasing sales of Genetron S5 instrument and 8-gene Lung Cancer Assay
- Development services: Continued strategic shift to biopharma services

Robust revenue growth in 2Q2021




IVD revenue as a percentage of total revenue increased in 2Q2021



Note:
(1) Unaudited financial numbers


Gross profit and margin

(RMB million)




Gross profit and margin (LDT)

(RMB million)




Gross profit and margin (IVD)

(RMB million)



Gross profit and margin (Development services)


(RMB million)



Note:
(1) Unaudited financial numbers


Selling expenses

(RMB million)




Administrative expenses

(RMB million)



R&D expenses

(RMB million)



■ Selling expenses

■ Percentage of total revenue

■ Administrative expenses

■ Percentage of total revenue

■ R&D expense

■ Percentage of total revenue


Note:
(1) Unaudited financial numbers

(in RMB million)	Second Quarter		
	Q2 2021	Q2 2020	Y/Y Change
Revenue	140.5	101.7	38.1%
Diagnosis & monitoring- LDT	87.1	75.8	15.0%
Diagnosis & monitoring- IVD	43.8	18.1	141.5%
Development services	9.5	7.8	21.8%
Gross margin	67.2%	63.1%	410bps
Selling expenses (% of rev)	63.0%	59.6%	340bps
R&D expenses (% of rev)	40.0%	29.3%	1070bps
Admin expenses (% of rev)	38.8%	27.4%	1140bps
Operating loss	(100.2)	(53.1)	-
Net loss	(92.1)	(2,832.4)	-
Non-IFRS loss ¹	(79.6)	(43.9)	-

As of June 30, 2021, cash and cash equivalents, restricted cash and current financial assets at fair value through profit or loss were RMB1,214.0 million

1. Non-IFRS loss represents net results excluding share-based expenses, fair value change and other loss of financial instruments with preferred rights. Please refer to appendix for the reconciliation of non-IFRS loss for the year/period to net loss for the year/period

RMB million



UNAUDITED NON-IFRS FINANCIAL MEASURES

	<u>For the three months ended,</u>	
	<u>June 30, 2020</u>	<u>June 30, 2021</u>
	RMB'000	RMB'000
Loss for the period	(2,832,363)	(92,146)
Adjustments:		
Share-based compensation	9,903	12,504
Fair value loss of financial instruments with preferred rights	2,778,591	-
Non-IFRS Loss	(43,869)	(79,642)
Attributable to:		
Owners of the Company	(43,869)	(79,316)
Non-controlling interests	-	(326)